US › Healthcare

Eledon Pharmaceuticals Inc (ELDN)

US · Healthcare · Biotechnology

$2.13-6.17%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-31.6M

EPS

$-0.19

EPS estimate

$-0.19

EPS came in at -0.19 against a street estimate of -0.19 — a beat of 0.0%.

Key statistics

Market cap

$173.1M

Forward P/E

5.4

P/B

6.70

Book value

$0.89

EPS (TTM)

$-0.90

52-week high

$4.60

52-week low

$1.35

50-day MA

$2.92

200-day MA

$3.07

Beta

0.85

Analyst view

Analysts rate Eledon Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $9.00.

Shareholding

Insiders

0.33%

Institutions

58.64%

Largest institutional holders

Fund	Stake
Bvf Inc	7.74%
BlackRock Inc	6.31%
Defilade Capital Management, L.P.	4.34%
Vanguard Capital Management, LLC	4.21%
The Goldman Sachs Group Inc	3.09%
Ensign Peak Advisors Inc	2.59%
Geode Capital Management, LLC	2.41%
Catalio Capital Management, LP	2.09%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eledon Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.